Methods
At our institution, LVAD implantation program for eligible patients with
heart failure was started in year 2017. During the period from 2017 to
2019, the overall number of patients submitted to LVAD implantation
using Heartmate3 was 28 patients, and 4 of them (14.3%) had sickle-cell
trait (SCT) hemoglobinopathy. After obtaining approval from the
Institutional Review Board, the medical records of the four SCT patients
were reviewed and we retrospectively conducted an analysis.